Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Nurix Therapeutics Inc (NASDAQ: NRIX) was $17.43 for the day, down -0.34% from the previous closing price of $17.49. In other words, the price has decreased by -$0.34 from its previous closing price. On the day, 1.69 million shares were traded. NRIX stock price reached its highest trading level at $17.74 during the session, while it also had its lowest trading level at $16.9766.
Ratios:
Our analysis of NRIX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.35 and its Current Ratio is at 5.35. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
On October 21, 2025, Mizuho started tracking the stock assigning a Outperform rating and target price of $24.
On March 17, 2025, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $16.Leerink Partners initiated its Market Perform rating on March 17, 2025, with a $16 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 18 ’25 when Ring Christine sold 3,760 shares for $17.90 per share. The transaction valued at 67,314 led to the insider holds 50,897 shares of the business.
CHRISTINE RING bought 7,520 shares of NRIX for $136,939 on Dec 18 ’25. On Nov 24 ’25, another insider, Ring Christine, who serves as the Chief Legal Officer of the company, sold 37,600 shares for $17.07 each. As a result, the insider received 641,697 and left with 50,897 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRIX now has a Market Capitalization of 1766865792 and an Enterprise Value of 967735296. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.11 while its Price-to-Book (P/B) ratio in mrq is 3.60. Its current Enterprise Value per Revenue stands at 11.564 whereas that against EBITDA is -3.731.
Stock Price History:
The Beta on a monthly basis for NRIX is 1.96, which has changed by -0.103536665 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, NRIX has reached a high of $22.50, while it has fallen to a 52-week low of $8.18. The 50-Day Moving Average of the stock is 8.51%, while the 200-Day Moving Average is calculated to be 45.54%.
Shares Statistics:
NRIX traded an average of 1.77M shares per day over the past three months and 1437110 shares per day over the past ten days. A total of 101.37M shares are outstanding, with a floating share count of 99.81M. Insiders hold about 1.53% of the company’s shares, while institutions hold 82.83% stake in the company. Shares short for NRIX as of 1765756800 were 13642687 with a Short Ratio of 7.72, compared to 1763078400 on 14076725. Therefore, it implies a Short% of Shares Outstanding of 13642687 and a Short% of Float of 15.160000000000002.
Earnings Estimates
Nurix Therapeutics Inc (NRIX) is presently subject to a detailed evaluation by 12.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.83, with high estimates of -$0.61 and low estimates of -$1.05.
Analysts are recommending an EPS of between -$2.48 and -$3.39 for the fiscal current year, implying an average EPS of -$3.1. EPS for the following year is -$3.41, with 13.0 analysts recommending between -$2.13 and -$4.46.
Revenue Estimates
For the next quarter, 16 analysts are estimating revenue of $16.72M. There is a high estimate of $22.5M for the next quarter, whereas the lowest estimate is $13.8M.
A total of 17 analysts have provided revenue estimates for NRIX’s current fiscal year. The highest revenue estimate was $108.78M, while the lowest revenue estimate was $70.4M, resulting in an average revenue estimate of $85.23M. In the same quarter a year ago, actual revenue was $54.55M
